ES2052995T3 - Pirroles sustituidos. - Google Patents

Pirroles sustituidos.

Info

Publication number
ES2052995T3
ES2052995T3 ES90103142T ES90103142T ES2052995T3 ES 2052995 T3 ES2052995 T3 ES 2052995T3 ES 90103142 T ES90103142 T ES 90103142T ES 90103142 T ES90103142 T ES 90103142T ES 2052995 T3 ES2052995 T3 ES 2052995T3
Authority
ES
Spain
Prior art keywords
substituted pyrroles
active substances
derivatives
substances
furandione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90103142T
Other languages
English (en)
Inventor
Peter David Davis
Christopher Huw Hill
Geoffrey Lawton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898904161A external-priority patent/GB8904161D0/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2052995T3 publication Critical patent/ES2052995T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Pyridine Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

EL INVENTO SE REFIERE A UN PIRROL SUSTITUIDO DE FORMULA (I); DESCRIBE LA PRODUCCION DEL COMPUESTO DE FORMULA (I) A PARTIR DE DERIVADOS DE FURANDINA, SIENDO X, Y -N=R O =O Y TRATA DE LA APLICACION DEL COMPUESTO DE FORMULA (I) COMO SUSTANCIA ACTIVA CARDIOVASCULAR, ANTIINFLAMATORIA, INMUNOLOGICA, ONCOLOGICA O BRONQUIO-PULMONAR O MATERIA ACTIVA EN EL TRATAMIENTO DE ASMA O AIDS. TENIENDO R1 A R8, R, X, Y, M Y N EL SIGNIFICADO DESCRITO EN LA PATENTE.
ES90103142T 1989-02-23 1990-02-19 Pirroles sustituidos. Expired - Lifetime ES2052995T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898904161A GB8904161D0 (en) 1989-02-23 1989-02-23 Substituted pyrroles
GB898928210A GB8928210D0 (en) 1989-02-23 1989-12-13 Substituted pyrroles

Publications (1)

Publication Number Publication Date
ES2052995T3 true ES2052995T3 (es) 1994-07-16

Family

ID=26295005

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90103142T Expired - Lifetime ES2052995T3 (es) 1989-02-23 1990-02-19 Pirroles sustituidos.

Country Status (20)

Country Link
EP (1) EP0384349B1 (es)
JP (1) JPH06102661B2 (es)
AT (1) ATE104972T1 (es)
AU (1) AU633051B2 (es)
CA (1) CA2010636C (es)
CZ (1) CZ284587B6 (es)
DE (1) DE59005491D1 (es)
DK (1) DK0384349T3 (es)
DZ (1) DZ1399A1 (es)
ES (1) ES2052995T3 (es)
FI (1) FI93447C (es)
HU (1) HU206351B (es)
IE (1) IE64184B1 (es)
IL (1) IL93433A (es)
MC (1) MC2096A1 (es)
NO (1) NO174891C (es)
NZ (1) NZ232589A (es)
PT (1) PT93246B (es)
RU (2) RU2142460C1 (es)
SK (1) SK278711B6 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
JPH07504673A (ja) * 1992-03-20 1995-05-25 ザ・ウエルカム・ファウンデーション・リミテッド 抗ウイルス活性を有するインドール誘導体
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
CA2137203C (en) * 1993-12-07 2006-11-28 William Francis Heath Jr. Protein kinase c inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
DE69418978T2 (de) * 1993-12-07 1999-10-28 Eli Lilly And Co., Indianapolis Synthese von Bisindolylmaleimiden
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
ATE456367T1 (de) * 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
ATE172463T1 (de) * 1994-08-04 1998-11-15 Hoffmann La Roche Pyrrolocarbazol
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
JPH10510281A (ja) * 1994-12-13 1998-10-06 エフ・ホフマン−ラ ロシュ アーゲー イミダゾール誘導体
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
EP0935463B1 (en) * 1996-10-31 2004-01-21 Harbor Branch Oceanographic Institution, Inc. Use of anti-neurogenic inflammatory compounds and compositions
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
AU6593600A (en) * 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
ES2233691T3 (es) 2000-07-27 2005-06-16 F. Hoffmann-La Roche Ag Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de la glicogen sintasa kinasa-3beta.
ATE326464T1 (de) 2000-12-08 2006-06-15 Ortho Mcneil Pharm Inc Indazolyl-substituierte pyrrolidin-verbindungen als kinase inhibitoren
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
EP1458713B1 (en) * 2001-12-27 2005-08-24 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
BRPI0413439A (pt) 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas
EP1745037B1 (en) * 2004-01-19 2013-01-02 Novartis AG Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases
EP1814883A1 (en) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
AU2005313485B2 (en) 2004-12-08 2011-02-03 Johannes Gutenberg-Universitat Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
DE602006017965D1 (de) 2005-02-09 2010-12-16 Arqule Inc Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
EP2246346B1 (en) * 2005-07-11 2012-10-24 Novartis AG Indolylmaleimide derivatives as protein kinase inhibitors
US7696222B2 (en) * 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
EP1980561B1 (en) 2007-03-30 2013-10-09 Nerviano Medical Sciences S.R.L. Substituted 1h-pyrazolo[3,4-b] pyridine derivatives active as kinase inhibitors
KR20100024494A (ko) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
CA2690782C (en) 2007-06-22 2016-02-02 Arqule, Inc. Compositions and methods for treatment of cancer
US8304425B2 (en) 2007-06-22 2012-11-06 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
US8637671B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
AU2014257578B2 (en) * 2013-04-23 2017-11-16 Laboratorios Del Dr. Esteve, S.A. Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
WO2016008966A1 (en) 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
US5049563A (en) * 1988-07-07 1991-09-17 Duphar International Research B.V. Annelated indoleketones with an imidazolylalkyl substituent

Also Published As

Publication number Publication date
JPH06102661B2 (ja) 1994-12-14
NO174891B (no) 1994-04-18
NO900855L (no) 1990-08-24
IL93433A (en) 1996-11-14
FI900863A0 (fi) 1990-02-21
NO900855D0 (no) 1990-02-22
EP0384349B1 (de) 1994-04-27
JPH02264776A (ja) 1990-10-29
PT93246B (pt) 1996-01-31
HUT53369A (en) 1990-10-28
AU5003390A (en) 1990-08-30
NO174891C (no) 1994-07-27
DK0384349T3 (da) 1994-09-05
PT93246A (pt) 1990-08-31
IL93433A0 (en) 1990-11-29
CZ284587B6 (cs) 1999-01-13
DZ1399A1 (fr) 2004-09-13
AU633051B2 (en) 1993-01-21
MC2096A1 (fr) 1991-02-15
FI93447B (fi) 1994-12-30
HU900846D0 (en) 1990-04-28
CA2010636A1 (en) 1990-08-23
ATE104972T1 (de) 1994-05-15
FI93447C (fi) 1995-04-10
HU206351B (en) 1992-10-28
NZ232589A (en) 1992-09-25
RU2014332C1 (ru) 1994-06-15
CZ85590A3 (cs) 1998-10-14
EP0384349A1 (de) 1990-08-29
SK85590A3 (en) 1998-01-14
IE900647L (en) 1990-08-23
RU2142460C1 (ru) 1999-12-10
IE64184B1 (en) 1995-07-12
SK278711B6 (sk) 1998-01-14
DE59005491D1 (de) 1994-06-01
CA2010636C (en) 1999-12-14

Similar Documents

Publication Publication Date Title
DE59005491D1 (de) Substituierte Pyrrole.
FI893433A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
RU93033479A (ru) Способ получения замещенных пирролов, способ получения фармацевтических препаратов
CA2107105A1 (en) Heterocyclic-cyclic amine derivatives
NO905608L (no) Fremgangsmaate for fremstilling av a-nor-steroid-3-karboksylsyrederivater.
DE3880047D1 (de) Zusammensetzung eines zusatzes.
DE122005000012I1 (de) N-(Pyrrolo(2-3-d)pyrimidin-3-ylacyl)-Glutamins{urederivate.
NO924598L (no) Fremstilling av substituerte piperidiner
NO971625L (no) Nye peptider med immunomodulatoriske effekter
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
ATE92469T1 (de) Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung.
FI942468A0 (fi) Kemialliset yhdisteet, niiden valmistus ja käyttö
ATE92070T1 (de) Azachromanderivate.
FI905930A7 (fi) Menetelmä uusien, farmakologisesti käyttökelpoisten bispilokarpiinihapon esterijohdannaisten valmistamiseksi
FI906162A0 (fi) Foerfarande foer framstaellning av 3-(n-metyl-n-alkyl)-amino-2-metoximetylenpropan-1-olderivat.
NO880405D0 (no) Fremgangsmaate til fremstilling av 3-fenyl-7h-tiazolo-/3,2-b//1,2,4/-tiazine-7-oner.
NO305556B1 (no) Tiokarbamoylforbindelser og anvendelse derav samt middel for beskyttelse av tekniske materialer
ATE97130T1 (de) 13-brom und 13, 14-dibrom-ergoline, ihre herstellung und verwendung in arzneimitteln.
EE9400233A (et) 1,5,6,7-tetrahüdro-4H-indasool-4-ooni sisaldav ravim, uus 1,5,6,7-tetrahüdro-4H-indasool-4-oon ja meetodid nende saamiseks
NO905569L (no) Fremgangsmaate for fremstilling av fettsyrehalogenider.
NO931072L (no) Fremgangsmaate for fremstilling av polyhydraksyfettsyreamider i naervaer av loesningsmiddler
BR1101036A (pt) Derivados de n-(pirrolo(2,3-d)pirimidin-3-ilacil)-ácido glutâmico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 384349

Country of ref document: ES